Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Kekić, Natalija (57201548083)"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - A developing country’s perspective in DAA era
    (2018)
    Karić, Uroš (57201195591)
    ;
    Pešić-Pavlović, Ivana (36473869000)
    ;
    Stevanović, Goran (15059280200)
    ;
    Korać, Miloš (10040016700)
    ;
    Nikolić, Nataša (58288723700)
    ;
    Radovanović-Spurnić, Aleksandra (57191847101)
    ;
    Barać, Aleksandra (55550748700)
    ;
    Mitrović, Nikola (55110096400)
    ;
    Marković, Aleksandar (57198206234)
    ;
    Marković, Marko (57534497700)
    ;
    Petković, Anita (57201547687)
    ;
    Ostojić, Ivana (56005428100)
    ;
    Peruničić, Sanja (57191926042)
    ;
    Kekić, Natalija (57201548083)
    ;
    Glidžić, Martina (57201551635)
    ;
    Đonin-Nenezić, Miljana (57201195027)
    ;
    Brmbolić, Branko (6701712863)
    ;
    Milošević, Ivana (58456808200)
    Introduction: Chronic Hepatitis C Virus (HCV) infection leads to progressive fibrosis making fibrosis staging necessary in the evaluation of such patients. Different fibrosis scores are emerging as possible non-invasive alternatives for liver biopsy. The Fibrosis-4 Index (FIB-4) and AST to Platelet Ratio Index (APRI) scores are the most widely used and the most extensively tested. This study aims to determine if it was possible to accurately use these to identify patients that are unlikely to have severe fibrosis. Methodology: One hundred and forty-two patients with chronic hepatitis C infection who underwent liver biopsy since January 1st 2014 until May 31st 2017 at the Hospital for Infectious and Tropical Diseases in Belgrade were analyzed. The FIB-4 and APRI scores were calculated for each patient and compared to histologically determined fibrosis stage. Results: A comprehensive statistical analysis was conducted in order to compare patients with and without severe fibrosis and to evaluate the accuracy of the fibrosis scores. Patients with non-severe fibrosis were younger, had higher platelet counts and lower transaminase levels. FIB-4 had an AUC of 0.875 and the APRI score had an AUC of 0.861. No patients with severe fibrosis or cirrhosis had a FIB-4 lower than 1.08. FIB-4 was superior to APRI in identifying patients with severe fibrosis in the study cohort. Conclusion: FIB-4 was superior to APRI in the recognition of severe fibrosis. FIB-4 may prove very useful in identifying patients without advanced liver disease, especially if other non-invasive methods are inaccessible. © 2018 Karić et al.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - A developing country’s perspective in DAA era
    (2018)
    Karić, Uroš (57201195591)
    ;
    Pešić-Pavlović, Ivana (36473869000)
    ;
    Stevanović, Goran (15059280200)
    ;
    Korać, Miloš (10040016700)
    ;
    Nikolić, Nataša (58288723700)
    ;
    Radovanović-Spurnić, Aleksandra (57191847101)
    ;
    Barać, Aleksandra (55550748700)
    ;
    Mitrović, Nikola (55110096400)
    ;
    Marković, Aleksandar (57198206234)
    ;
    Marković, Marko (57534497700)
    ;
    Petković, Anita (57201547687)
    ;
    Ostojić, Ivana (59954448700)
    ;
    Peruničić, Sanja (57191926042)
    ;
    Kekić, Natalija (57201548083)
    ;
    Glidžić, Martina (57201551635)
    ;
    Đonin-Nenezić, Miljana (57201195027)
    ;
    Brmbolić, Branko (6701712863)
    ;
    Milošević, Ivana (58456808200)
    Introduction: Chronic Hepatitis C Virus (HCV) infection leads to progressive fibrosis making fibrosis staging necessary in the evaluation of such patients. Different fibrosis scores are emerging as possible non-invasive alternatives for liver biopsy. The Fibrosis-4 Index (FIB-4) and AST to Platelet Ratio Index (APRI) scores are the most widely used and the most extensively tested. This study aims to determine if it was possible to accurately use these to identify patients that are unlikely to have severe fibrosis. Methodology: One hundred and forty-two patients with chronic hepatitis C infection who underwent liver biopsy since January 1st 2014 until May 31st 2017 at the Hospital for Infectious and Tropical Diseases in Belgrade were analyzed. The FIB-4 and APRI scores were calculated for each patient and compared to histologically determined fibrosis stage. Results: A comprehensive statistical analysis was conducted in order to compare patients with and without severe fibrosis and to evaluate the accuracy of the fibrosis scores. Patients with non-severe fibrosis were younger, had higher platelet counts and lower transaminase levels. FIB-4 had an AUC of 0.875 and the APRI score had an AUC of 0.861. No patients with severe fibrosis or cirrhosis had a FIB-4 lower than 1.08. FIB-4 was superior to APRI in identifying patients with severe fibrosis in the study cohort. Conclusion: FIB-4 was superior to APRI in the recognition of severe fibrosis. FIB-4 may prove very useful in identifying patients without advanced liver disease, especially if other non-invasive methods are inaccessible. © 2018 Karić et al.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback